Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$3.44 USD
-0.06 (-1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Trevi Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 34 | 30 | 32 | 32 | 27 |
Income After Depreciation & Amortization | -34 | -30 | -32 | -32 | -27 |
Non-Operating Income | 5 | 2 | 0 | 0 | 1 |
Interest Expense | 0 | 1 | 1 | 0 | 0 |
Pretax Income | -29 | -29 | -34 | -33 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -29 | -34 | -33 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -29 | -34 | -33 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -34 | -29 | -32 | -32 | -27 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -34 | -30 | -32 | -32 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 99.03 | 64.54 | 22.84 | 18.06 | 11.74 |
Diluted EPS Before Non-Recurring Items | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 |
Diluted Net EPS (GAAP) | -0.29 | -0.45 | -1.49 | -1.81 | -2.28 |
Fiscal Year end for Trevi Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 13.29 | 11.90 | 8.94 | 9.04 | 8.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.29 | -11.90 | -8.94 | -9.04 | -8.38 |
Non-Operating Income | 0.93 | 1.00 | 1.13 | 1.34 | 1.36 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 |
Pretax Income | -12.36 | -10.91 | -7.80 | -7.71 | -7.18 |
Income Taxes | -0.01 | -0.01 | 0.00 | -0.01 | -0.03 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -12.35 | -10.90 | -7.81 | -7.70 | -7.15 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.35 | -10.90 | -7.82 | -7.70 | -7.15 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 101.04 | 99.52 | 99.49 | 99.33 | 98.70 |
Diluted EPS Before Non-Recurring Items | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 |
Diluted Net EPS (GAAP) | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 |